GNPXGenprex Inc
GNPX
Genprex Inc14,925
Mkt Cap
$4.36MVolume
252,799.0052W High
$55.0052W Low
$1.71PE Ratio
-0.04GNPX Fundamentals
Price
$1.88Prev Close
$1.92Open
$1.9450D MA
$2.23Beta
1.49Avg. Volume
1.21MEPS (Annual)
-$266.95P/B
2.46Rev/Employee
$0.00$1.81
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting Genprex Collaborators to Present...
PR Newswire·4d ago
Genprex to Participate at BIO Europe Spring 2026
Genprex to Participate at BIO Europe Spring 2026 Genprex to Participate at BIO Europe Spring 2026 PR Newswire AUSTIN, Texas, March 10, 2026 AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc...
PR Newswire·12d ago
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa Gene Therapy in Combination with Immunotherapies to Treat Cancer
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa Gene Therapy in Combination with Immunotherapies to Treat Cancer Genprex Strengthens Intellectual Property...
PR Newswire·27d ago
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) DelveInsight
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast...
PR Newswire·1mo ago
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2...
PR Newswire·3mo ago
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer...
PR Newswire·4mo ago
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials PR Newswire AUSTIN...
PR Newswire·4mo ago
Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1...
PR Newswire·4mo ago
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer Genprex Announces European Patent Office's Intent...
PR Newswire·5mo ago
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market...
PR Newswire·5mo ago
<
1
2
...
>